Recent advances in clinical research on aflibercept treating fundus vascular diseases
10.13389/j.cnki.rao.2017.0227
- VernacularTitle:阿柏西普治疗眼底血管性疾病的临床研究新进展
- Author:
Hongqiang ZOU
;
Hongqin TIAN
;
Yanping ZHANG
;
Rongxin LI
- Keywords:
aflibercept;
vascular endothelial growth factor;
macular degeneration;
macular edema
- From:
Recent Advances in Ophthalmology
2017;37(9):894-897
- CountryChina
- Language:Chinese
-
Abstract:
Aflibercept is a soluble fusion protein which combines ligand-binding elements taken from the extracellular components of vascular endothelial growth factor (VEGF) receptor-1 and receptor-2 fused to the Fc portion of IgG,and it is a novel antiVEGF drug,which can reduce vascular permeability and inhibit neoangiogenesis by binding VEGF tightly.A large number of phase Ⅲ clinical trials have demonstrated the satisfactory outcomes of aflibercept in the management of neovascular age-related macular degeneration,macular edema secondary to retinal vein occlusion or macular edema and other retinal vascular diseases.Moreover,intravitreal injection of afiibercept can improve the visual acuity and attenuate the fundus lesion,which provides a new drug option for physicians.The review will summarize the chemical properties of aflibercept and its application,safety and efficacy of aflibercept for the treatment of retinal vascular diseases.
